🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Naren Tallapragada Yes!! Exactly, a major advantage of using AI for hit identification is not just that it’s faster and cheaper (though saving a year and a few tens of millions dollars is nice!), but that it is compatible with low/medium throughput amazing assays!

Now you can avoid Matrigel like the plague!

Biology is poised for its DeepSeek moment. Never underestimate the power of clever humans constrained by compute.

Compute isn't the rate limiter (yet). Data definitely is. Relatively speaking, biological datasets are tiny and marred by experimental bias, protocol incongruences, and metadata gaps. Scaling compute too much on these repos risks overfitting (a common issue in bio).

It’s been a tough few weeks. My 10yo daughter was diagnosed with a very rare, aggressive cancer called interdigitating dendritic cell sarcoma (IDCS). I’m reaching out to identify clinicians/patients who have encountered pediatric IDCS, indeterminate dendritic cell histiocytosis

Check out the latest episode of Data in Biotech, where Naren Tallapragada talks about Tessel Bio’s unique approach to drug discovery, which involves "reverse engineering" chronic diseases: youtube.com/watch?v=H5x6JG…

Exclusive: Amplify Partners has raised $200 million for its first biotech-specific fund Targeting ~20 investments of $1.5m-$10m in pre-seed/seed/Series A-stage startups. The Silicon Valley VC has also hired Elliot Hershberg as a partner: endpoints.news/amplify-raises…